Simcere Zaiming to present the latest clinical progresses of three products in its portfolio at WCLC 2023
The First Subject Dosed with SIM0278, an Innovative IL-2 mu-Fc Independently Developed by Simcere Pharmaceutical
Positive Results from Phase II Clinical Study of JAK1 Inhibitor for AS Treatment Jointly Introduced by Simcere Pharmaceutical and Lynk Pharmaceuticals
Simcere Zaiming Partners with MabPharm on anti-EGFR Monoclonal Antibody CMAB009 in China
COSELA® new indication NDA accepted by China NMPA
Feng Fei, Secretary of the CPC Hainan Provincial Committee, Visited Hainan Simcere Pharmaceutical
Engineering cytokines for cancer immunotherapy: a systematic review by Simcere scientists published in Frontiers in Immunology
COSELA® and Endostar® Receive Endorsement in Chinese Medical Association's Lung Cancer Treatment Guidelines
Sim0278 injection (il-2 mutant fc fusion protein) obtained clinical trial approval, exploring solutions to continuous medication disturbance for hundreds of millions of atopic dermatitis patients
The hypnotics Daridorexant hydrochloride tablets obtained the clinical trial approval issued by the national medical products administration